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Abstract
Vulval development in Caenorhabditis elegans serves as an excellent model to examine the crosstalk between different
conserved signaling pathways that are deregulated in human cancer. The concerted action of the RAS/MAPK, NOTCH, and
WNT pathways determines an invariant pattern of cell fates in three vulval precursor cells. We have discovered a novel form
of crosstalk between components of the Insulin and the RAS/MAPK pathways. The insulin receptor DAF-2 stimulates, while
DAF-18 PTEN inhibits, RAS/MAPK signaling in the vulval precursor cells. Surprisingly, the inhibitory activity of DAF-18 PTEN
on the RAS/MAPK pathway is partially independent of its PIP3 lipid phosphatase activity and does not involve further
downstream components of the insulin pathway, such as AKT and DAF-16 FOXO. Genetic and biochemical analyses indicate
that DAF-18 negatively regulates vulval induction by inhibiting MAPK activation. Thus, mutations in the PTEN tumor
suppressor gene may result in the simultaneous hyper-activation of two oncogenic signaling pathways.
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Introduction
PTEN (Phosphatase and TENsin homologue) is the second-
most frequently somatically mutated tumor suppressor gene in
human cancer. PTEN is often inactivated in glioblastoma,
melanoma, prostate and endometrial neoplasia [1]. Germline
mutations in PTEN are also known to cause a variety of rare
syndromes, collectively known as the PTEN hamartoma tumor
syndromes (PHTS) [2]. Cowden syndrome is the best-described
syndrome within PHTS, with approximately 80% of patients
carrying germline PTEN mutations [3]. The main reported
function of PTEN is as a lipid phosphatase, which dephosphor-
ylates PhosphatidylInositol(3,4,5)-trisphosphate (PIP3) at position
3, thereby inhibiting the insulin pathway [4]. However, PTEN can
also act as a dual-specificity tyrosine and serine/threonine protein
phosphatase [5,6]. The catalytic phosphatase domain of PTEN
(amino acids 123–131) contains several conserved amino acids,
mutations of which affect the efficiency and specificity of the
phosphatase activity [7]. One such mutation is G129E, which
causes PTEN to lose its lipid phosphatase activity while retaining
most of its protein phosphatase activity [4,5]. Using the G129E
mutation, numerous reports have provided evidence for a crucial
role of PTEN protein phosphatase activity in regulating cell
migration, invasion and spreading independently of the canonical
insulin signaling pathway. For example, PTEN G129E regulates
cell migration, spreading, and the formation of focal adhesions [8].
Moreover, PTEN G129E binds and de-phosphorylates the Focal
Adhesion Kinase FAK in vitro [8]. In glioblastoma cells injected
into nude mice, PTEN G129E expression inhibits cell invasion,
accompanied by decreased FAK phosphorylation without chang-
ing the activity of the AKT kinase [6,9]. Additionally, PTEN binds
and dephosphorylates the adaptor protein Shc to modulate cell
motility [10].
The daf-18 gene encodes the single PTEN ortholog in C. elegans
[11]. Under favorable growth conditions, C. elegans larvae pass
through four distinct larval stages termed L1 to L4. However,
under conditions of starvation or overcrowding, the L1 larvae
enter a long-lived, stress resistant alternative developmental stage
called the dauer larva stage. DAF-18 PTEN controls entry into the
larval dauer stage, life span, neurite outgrowth and cell-cycle
progression, mainly by inhibiting the insulin signaling pathway
[12–14]. Human PTEN can functionally replace C. elegans DAF-18
to rescue the daf-18(lf) DAuer Formation defective (DAF-d)
phenotype [15].
In the presence of abundant food, binding of various insulin
ligands to the DAF-2 insulin receptor causes the activation of
AGE-1, the only type I phosphatyidlinositol-3-kinase (PI3K)
encoded by the C. elegans genome [11]. AGE-1 phosphorylates
PI(4,5)P2 to PI(3,4,5)P3, which acts as a second messenger. PIP3
then activates the AKT-1 and AKT-2 kinases that phosphorylate
and thereby inhibit the FOXO transcription factor DAF-16 [16].
In the absence of the insulin signal, non-phosphorylated DAF-16
enters the nucleus and activates genes promoting entry into the
dauer stage [17]. The main reported function of DAF-18 PTEN is
to antagonize the insulin pathway by dephosphorylating PIP3 [14].
Loss of daf-18 thus leads to hyper-activation of the insulin pathway
and a DAF-d phenotype, while loss of daf-2 or age-1 function leads
to a DAuer Formation constitutive (DAF-c) phenotype.
Recent evidence indicates that similar to mammalian PTEN, C.
elegans DAF-18 can also act as a protein phosphatase to regulate
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insulin-independent events. For example, DAF-18 PTEN directly
binds and dephosphorylates the ephrin receptor tyrosine kinase
VAB-1 to regulate oocyte maturation in the hermaphrodite
germline [18]. Moreover, multiple genes causing synthetic lethality
in combination with daf-18(lf) have been identified, pointing to
additional functions of DAF-18 besides its role in insulin signaling
[19].
The development of the C. elegans hermaphrodite vulva, the egg-
laying organ, is one of the best-characterized models for
organogenesis [20]. The interplay between the conserved RAS/
MAPK, NOTCH, and WNT signaling pathways specifies two
distinct vulval cell fates. Beginning in the L2 stage, the gonadal
Anchor Cell (AC) releases the EGF ligand LIN-3, which activates
the EGF receptor homolog LET-23 in the six Vulval Precursor
Cells (VPCs). The VPC located nearest the AC (P6.p) receives
most of the inductive LIN-3 EGF signal and hence exhibits the
strongest activity of the RAS/MAPK pathway, allowing P6.p to
adopt the primary (1u) vulval cell fate. Consequently, P6.p
produces a lateral signal that activates the LIN-12 NOTCH
signal in the neighboring VPCs P5.p and P7.p. Notch signaling in
these two VPCs induces them to adopt the secondary (2u) cell fate
and at the same time blocks transduction of the inductive LIN-3
signal by inhibiting MAPK activation. The 1u VPC P6.p and the
2u VPCs P5.p and P7.p each go through three rounds of cell
division to generate 22 cells that form the vulva. The remaining
three distal VPCs (P3.p, P4.p and P8.p) adopt the non-vulval 3u
fate, which divide once and then fuse with the surrounding
hypodermis (hyp7).
Mutations in genes encoding components of the RAS/MAPK,
NOTCH, and WNT signaling pathways change the patterning of
the VPC fates, which can readily be quantified. For example,
mutations that hyperactivate the RAS/MAPK pathway cause the
induction of more than three VPCs, resulting in a Multivulva
(Muv) phenotype. On the other hand, mutations that cause a
decrease in RAS/MAPK pathway activity, lead to the induction of
fewer than three VPCs, a phenotype called Vulvaless (Vul).
In this work, we have discovered and characterized a new mode of
crosstalk between components of the insulin and the RAS/MAPK
pathways. Using genetic and biochemical epistasis analyses, we found
that the insulin receptor DAF-2 stimulates while DAF-18 PTEN
inhibits RAS/MAPK signaling in the VPCs. Surprisingly, part of the
inhibitory activity of DAF-18 on the RAS/MAPK pathway is
independent of its PIP3 lipid phosphatase activity and does not
involve further downstream components of the insulin pathway. Our
results indicate that DAF-18 negatively regulates vulval induction
most likely by inhibiting MAP kinase MPK-1 signaling.
Results
daf-18 inhibits vulval induction independently of the
canonical insulin signaling pathway
In our previous work, we reported first evidence for a crosstalk
between the DAF-2 insulin receptor and the RAS/MAPK
signaling pathway during vulval development [21]. To further
investigate this interaction, we performed a systematic epistasis
analysis by combining various mutations in the insulin and RAS/
MAPK signaling pathways and quantifying the levels of vulval
induction (Table 1). As reported previously, a reduction-of-
function (rf) mutation in the insulin receptor daf-2 partially
suppressed the Muv phenotype of let-60 ras gain-of-function (gf)
animals (Table 1, rows 1, 2) [21]. Conversely, a loss-of-function (lf)
mutation in the PTEN homolog daf-18 strongly enhanced the let-
60(gf) Muv phenotype (Table 1, row 3). Moreover, daf-18(lf)
suppressed the vulvaless (Vul) phenotype caused by mutations in
the EGF receptor let-23 or in its cofactor lin-2, which activates the
RAS/MAPK signaling pathway in the VPCs (Table 1, rows 4–7).
Since DAF-18 PTEN counteracts the type I phosphatidyl-inositol-
3 kinase (PI3K) AGE-1 that transduces the insulin signal
downstream of DAF-2, we tested if an age-1(lf) mutation could
revert the enhanced vulval induction caused by daf-18(lf).
Surprisingly, age-1(lf) only partially suppressed the increase in
vulval induction caused by daf-18(lf), both in the let-60(gf) and the
lin-2(lf) backgrounds (Table 1, rows 8, 9). Also, the daf-2(rf)
mutation only partially reverted the enhancement of the let-60(gf)
Muv phenotype by daf-18(lf) (Table 1, row 10), suggesting that
DAF-18 inhibits vulval induction to some extent independently of
DAF-2 and AGE-1. However, mutations in further downstream
components of the DAF-2 insulin pathway had no detectable effect
on vulval induction. For example, a gf mutation in akt-1, which
encodes one of the two AKT homologues transducing the insulin
signal downstream of AGE-1 [16], did not suppress the let-23(rf)
Vul phenotype (Table 1, row 11), and a lf mutation in akt-1 did not
suppress the daf-18(lf) let-60(gf) Muv phenotype (Table 1, row 12).
To examine a possible redundancy between the two akt genes, we
performed akt-2 RNAi in daf-18(lf) let-60(gf); akt-1(lf) triple
mutants, but observed no reduction in vulval induction compared
to the RNAi controls (Table 2, rows 1, 2). Also, a lf mutation in
daf-16, which encodes a FOXO transcription factor that is
negatively regulated by the insulin pathway, did not enhance the
let-60(gf) Muv phenotype (Table 1, row 13).
We further tested the role of AGE-1 during vulval development.
Since age-1(lf) leads to a constitutive dauer phenotype (DAF-c) that
is maternally rescued, homozygous age-1(lf) worms could only be
analyzed in the F1 progeny of heterozygous age-1(lf)/+ parents or
when rescued by the daf-16(lf) mutation. Our analysis indicated
that age-1 also exhibits a partial maternal rescue in vulval induction
since the homozygous age-1(lf); let-60(gf) progeny obtained from
heterozygous age-1(lf)/+ parents displayed similar levels of vulval
induction as let-60(gf) single mutants (Table 1, row 14). In contrast,
homozygous age-1(lf); let-60(gf) double mutants maintained in the
daf-16(lf) background exhibited a partially suppressed Muv
phenotype, though age-1(lf) suppressed the let-60(gf) Muv pheno-
type to a lesser extent than daf-2(rf) (Table 1, row 15, p-
value#0.05 compared to row 2).
Author Summary
The human tumor suppressor PTEN is mutated in many
different types of cancer. Using the roundworm C. elegans
as a model to study how cells communicate during animal
development, we discovered a new mechanism by which
PTEN inhibits the activity of the oncogenic RAS/MAPK
signaling pathway. Focusing on the development of the
vulva, the egg-laying organ of the hermaphrodite, as a
model to investigate the regulation of RAS/MAPK signal-
ing, we could distinguish between two distinct inhibitory
activities of PTEN on the RAS/MAPK signaling pathway. On
the one hand, PTEN acts as a lipid phosphatase that
inhibits the production of PIP3, which in turn stimulates
RAS/MAPK signaling. On the other hand, PTEN acts as a
protein phosphatase that negatively regulates RAS/MAPK
signaling by inhibiting signal transduction at the level of
the MAPK, which is a key component in the pathway.
Understanding the detailed molecular mechanism by
which the PTEN tumor suppressor homolog regulates
signal transduction in C. elegans can help predict the
consequences of mutations in human PTEN for cancer
development in humans.
C. elegans PTEN Inhibits MAPK
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Taken together, the genetic analysis indicates that the DAF-2
insulin receptor promotes and DAF-18 PTEN inhibits vulval
induction. DAF-2 and DAF-18 both regulate vulval induction
through AGE-1-dependent as well as AGE-1-independent path-
ways that do not utilize the canonical insulin pathway downstream
of AGE-1.
DAF-18 inhibits vulval induction independently of other
PI3Ks
AGE-1 is the only C. elegans member of the type I family of
PI3Ks, which convert PI(4,5)P2 into PI(3,4,5)P3. To further
investigate the AGE-1-independent effect of DAF-18 on vulval
induction, we tested the roles of alternative PI3Ks that can
phosphorylate PIs at position 3. vps-34 encodes a type III PI3K,
which catalyzes the production of PI(3)P1, and piki-1 encodes a
type II PI3K involved in the engulfment of apoptotic cell corpses
[22]. In order to examine the role of these alternative PI3Ks
during vulval induction, we performed RNAi against vps-34 and
piki-1 in age-1(lf); daf-18(lf); lin-2(lf) animals and tested for a further
reduction of vulval induction. RNAi to vps-34 and piki-1 has been
previously shown to be effective in different tissues [23,24].
Neither vps-34 nor piki-1 RNAi caused any significant reduction in
the number of induced VPCs when compared to control (gfp)
RNAi animals (Table 2, rows 3–5). Furthermore, vps-34 and piki-1
RNAi in an age-1(lf); daf-18(lf) let-60(gf) background did not cause a
decrease in vulval induction (Table 2, rows 6–8). It thus seems
unlikely that an alternative PI3K acts redundantly with AGE-1
during vulval induction, further supporting our observation that
DAF-18 regulates vulval induction not only by regulating PIP3
levels but also via a lipid phosphatase-independent activity.
daf-18 inhibits 1u vulval cell fate specification
To characterize the nature of the cell fate transformation caused
by daf-18(lf), we quantified the levels of the EGL-17::CFP reporter,
whose expression is induced by RAS/MAPK signaling in the 1u
vulval cell lineage [25] and of the LIP-1::GFP reporter whose
expression is induced by LIN-12 NOTCH signaling in the 2u
vulval cell lineage [26].
daf-18(lf) let-60(gf) double mutants showed an increased
frequency of adjacent VPC descendants expressing high levels of
EGL-17::CFP when compared to let-60(gf) single mutants
(Figure 1A–1D). Specifically, in daf-18(lf); let-60(gf) double mutants
27% of adjacent VPC descendants showed strong EGL-17::CFP
expression (i.e. at least 50% of the signal intensity seen in the P6.p
lineage) versus 16% in let-60(gf) single mutants (Figure 1G).
Furthermore, while the 2u P5.p and P7.p descendants in the wild-
type displayed weak (i.e. less than 50% of the P6.px signal
intensity) EGL-17::CFP expression in 22% of the cases, 52% of
daf-18(lf) single mutants showed EGL-17::CFP expression in the 2u
cells (Figure 1G).
Besides the slight increase in EGL-17::CFP expression, the
morphology of the vulval invagination at the L4 larval stage was
changed in daf-18(lf) let-60(gf) double mutants. The vulval
invagination formed by the P5.p to P7.p descendants of most let-
60(gf) single mutants resembles the single invagination formed in
the wild-type (Figure 1E). In daf-18(lf) let-60(gf) double mutants, on
the other hand, the P5.p to P7.p descendants were often
completely detached from the cuticle, resulting in an abnormal
shape of the vulval invagination (Figure 1F) (37% detached P5.p
and/or P7.p descendants in daf-18(lf) let-60(gf) versus 3% detached
in let-60(gf), n = 54 and n= 35, respectively). A detachment of the
P5.p and P7.p descendants from the cuticle is indicative of a 2u to
1u cell fate transformation as it has been observed in mutants
exhibiting elevated MAPK activity in the 2u lineage [27].
In contrast to the 1u fate marker EGL-17::CFP, expression of
the 2u fate marker LIP-1::GFP was not changed in daf-18(lf)
mutants. In particular, LIP-1::GFP levels in the P5.p and P7.p
Table 1. Epistasis analysis between the insulin and RAS/
MAPK pathways.
genotype Induction±SE % Vul % Muv n
1 let-60(gf) 4.1660.05 0.00 79.1 283
2 daf-2(rf); let-60(gf) 3.2460.11***(1) 0.00 19.3 31
3 daf-18(lf) let-60(gf) 4.9960.05***(1) 0.00 96.4 221
4 let-23(rf) 0.5560.08 93.8 0.00 129
5 let-23(rf); daf-18(lf) 1.9060.10***(4) 63.9 6.8 133
6 lin-2(lf) 1.3460.19 73.8 0.00 42
7 daf-18(lf); lin-2(lf) 2.5060.12***(6) 35.5 1.7 59
8 age-1(lf); daf-18(lf)
let-60(gf)
4.6160.08***(1) 0.00 94.7 113
9 age-1(lf); daf-18(lf);
lin-2(lf)
2.1560.16***(6) 53.1 6.1 49
10 daf-2(rf); daf-18(lf)
let-60(gf)
4.4060.17(1) 0.00 88.0 25
11 let-23(rf); akt-1(gf) 0.3660.13(4) 94.9 0.00 39
12 daf-18(lf) let-60(gf);
akt-1(lf)
4.8060.29(3) 0.00 80 15
13 daf-16(lf); let-60(gf) 4.1860.11(1) 0.00 77.5 80
14 age-1(lf); let-60(gf){ 4.0860.06(1) 0.00 76.2 164
15 age-1(lf); daf-16(lf);
let-60(gf)
3.6260.15**(1) 0.00 54.1 24
SE indicates the standard error of the mean. % Vul indicates the fraction of
animals with less than three induced VPCs. % Muv indicates the fraction of
animals with more than three induced VPCs. Induction indicates the average
number of induced VPCs per animal.
**indicates a p-value#0.005;
***indicates a p-value#0.0005. Numbers in brackets indicate the row against
which a t-test was performed. Alleles used: LG I: daf-16(mu86), LG II: age-
1(mg44), let-23(sy1), LG III: daf-2(e1370), LG IV: let-60(n1046), daf-18(ok480), LG V:
akt-1(ok525lf), akt-1(mg144af), LG X: lin-2(n397).
{F1 progeny of heterozygous age-1(lf)/+ parents.
doi:10.1371/journal.pgen.1002881.t001
Table 2. RNAi against akt-2 and alternative PI3Ks.
genotype RNAi
Induction
±SE
%
Vul
%
Muv n
1 daf-18(lf) let-60(gf); akt-1(lf) gfp 5.4160.12 0.00 100 17
2 daf-18(lf) let-60(gf); akt-1(lf) akt-2 5.5360.18 0.00 94.4 18
3 age-1(lf);daf-18(lf);lin-2(lf) gfp 1.5960.34 71 12 17
4 age-1(lf);daf-18(lf);lin-2(lf) vps-34 1.6060.28 65 0 20
5 age-1(lf);daf-18(lf);lin-2(lf) piki-1 1.6960.31 69 6 16
6 age-1(lf);daf-18(lf);let-60(gf) gfp 5.1460.20 0 94 17
7 age-1(lf);daf-18(lf);let-60(gf) vps-34 5.4060.16 0 100 15
8 age-1(lf);daf-18(lf);let-60(gf) piki-1 5.4460.12 0 100 17
SE indicates the standard error of the mean. % Vul indicates the fraction of
animals with less than three induced VPCs. % Muv indicates the fraction of
animals with more than three induced VPCs. Induction indicates the average
number of induced VPCs per animal. Alleles used: LG II: age-1(mg44), LG IV: daf-
18(ok480), let-60(n1046), LGV: akt-1(ok525lf), LG X: lin-2(n397).
doi:10.1371/journal.pgen.1002881.t002
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descendants were unchanged in daf-18(lf) let-60(gf) double mutants
compared to let-60(gf) single mutants (Figure 1H–1J).
Thus, daf-18(lf) enhances specification of the 1u cell fate and
causes a partial 2u to 1u fate transformation in P5.p and P7.p
without affecting the strength of the lateral LIN-12 NOTCH
signal.
daf-18 negatively regulates vulval induction downstream
of sos-1 and upstream or at the level of mpk-1
Since EGFR/RAS/MAPK signaling induces the 1u vulval cell
fate and daf-18(lf) mutants exhibited an increased expression of the
1u cell fate marker EGL-17::CFP, we sought to determine at what
level DAF-18 inhibits the activity of the EGFR/RAS/MAPK
signaling pathway. For this purpose, we performed further
epistasis analysis combining daf-18(lf) with mutations in different
components of the RAS/MAPK pathway. Even though daf-18(lf)
single mutants showed no obvious changes in the vulval fate
pattern (Table 3, rows 1, 2), daf-18(lf) increased the levels of vulval
induction in most of mutants in the RAS/MAPK pathway tested,
confirming that DAF-18 negatively regulates the RAS/MAPK
signaling during vulval induction. For example, when combined
with mutations in different positive regulators of the RAS/MAPK
pathway such as let-23(rf), lin-2(lf) or lin-45(rf), daf-18(lf) signifi-
cantly suppressed the Vul phenotype of these mutants (Table 3,
rows 5–8 and 11–12). In particular, daf-18(lf) suppressed a lf
mutation in the RAS-GEF sos-1 when assayed in the let-60(gf)
background to rescue the lethality caused by sos-1(lf), placing daf-
18 function downstream of sos-1 (table 3, rows 9–10). However,
since vulval induction in sos-1(lf); let-60(gf) animals is partly
sensitive to the inductive anchor cell signal [28], we cannot
exclude the possibility that DAF-18 might inhibit RAS/MAPK
signaling through a SOS-1 independent branch of the pathway. As
an exception, daf-18(lf) did not suppress the Vul phenotype of lin-
3(rf) mutants (Table 3, rows 3–4), suggesting that daf-18(lf) alone is
not sufficient to activate the RAS/MAPK pathway in the absence
of the inductive AC signal. Furthermore, daf-18(lf) did not affect
the completely penetrant Vul phenotype caused by mpk-1(lf)
(Table 3, rows 13–14). Taken together, our epistasis analysis
indicates that DAF-18 inhibits RAS/MAPK signaling downstream
of or in parallel with the RAS-GEF SOS-1 and upstream or at the
level of the MAP kinase MPK-1.
DAF-18 negatively regulates MPK-1 but not MEK-2
phosphorylation
Activation of the RAS/MAPK pathway results in an increased
phosphorylation and activity of the downstream effectors RAF,
MAPK kinase (MEK) and MAPK. We thus examined if daf-18(lf)
mutants exhibit elevated levels of MEK and MAPK phosphory-
lation. Western blots of extracts from L4 larvae were probed with
antibodies against mono-phosphorylated MEK (pMEK-2) and di-
phosphorylated MAPK (dpMPK-1). Although the C. elegans
genome encodes two MEK genes, MEK-1 and MEK-2, the
Figure 1. DAF-18 inhibits 16 vulval fate specification. (A) Expression of the 1u cell fate marker EGL-17::CFP in let-60(gf) single and (B) daf-18(lf)
let-60(gf) double mutants at the Pn.px stage. (C and D) show the corresponding Nomarski images of the animals shown in (A) and (B), respectively. (E)
Morphology of the vulval invagination in a let-60(gf) mutant at the Pn.pxxx stage. Note that the descendants of P5.p and P7.p remain attached to the
cuticle, which is characteristic of the 2u cell fate. (F) P5.p and P7.p often detach from the cuticle in daf-18(lf) let-60(gf) animals, resulting in a broad
invagination with abnormal morphology. (G) Quantification of the 1u fate marker EGL-17::CFP expression at the Pn.px and Pn.pxx stages in the
indicated genetic backgrounds. Dark blue represents cells with high EGL-17::CFP expression, corresponding to at least 50% of the intensity observed
in the P6.px(x) cells, light blue represents cells with clearly visible but less than 50% of the P6.px(x) signal, and white spaces represent cells with
undetectable levels of EGL-17::CFP. (H) Expression of the 2u fate marker LIP-1::GFP in let-60(gf) and (I) daf-18(lf) let-60(gf) animals. (J) Quantification of
LIP-1::GFP expression in the P5.p through P7.p descendants. Signal intensities are indicated relative to P6.px(x) in let-60(gf).
doi:10.1371/journal.pgen.1002881.g001
C. elegans PTEN Inhibits MAPK
PLOS Genetics | www.plosgenetics.org 4 August 2012 | Volume 8 | Issue 8 | e1002881
phosphorylation site in human MEK to which the phospho-MEK
antibody was raised (S217/S221) is only conserved in C. elegans
MEK-2. Thus, we were able to specifically detect phosphorylated
MEK-2 in whole animal extracts. Wild-type and daf-18(lf) L4
larvae contained only low levels of pMEK-2 and dpMPK-1 that
could not be reliably quantified. As expected, let-60(gf) single
mutants contained significantly higher levels of pMEK-2 and
dpMPK-1 than wild-type larvae (Figure 2A and 2C). However, we
observed no further increase in pMEK-2 levels in daf-18(lf) let-
60(gf) double compared to let-60(gf) single mutants (Figure 2B). In
contrast, dpMPK-1 levels were around two-fold increased daf-
18(lf) let-60(gf) compared to let-60(gf) mutants (Figure 2D).
Together with the genetic epistasis data presented above, the
increase in MPK-1 phosphorylation in the absence of a significant
change in MEK-2 phosphorylation indicates that DAF-18 most
likely inhibits vulval induction at the level of MPK-1. Finally, the
fact that we observed increased MPK-1 phosphorylation in total
worm lysates suggests a global regulation of the RAS/MAPK
pathway by DAF-18, probably including the germline.
daf-18 expression in the VPCs inhibits vulval induction
To further investigate the role of DAF-18 during vulval
induction, we constructed a translational reporter by inserting a
gfp cassette at the 39 end of the ORF in a genomic daf-18 fragment
(Figure 3). This DAF-18::GFP reporter rescued both the dauer
defective (DAF-d) phenotype (data not shown) as well as the vulval
phenotypes of daf-18(lf) with similar efficiency as a 6.5 kb genomic
fragment spanning the entire daf-18 locus (Figure 4). DAF-18::GFP
expression was observed in many tissues during all larval stages,
including the developing vulva, the uterus, the ventral nerve cord
and the distal tip cells (data not shown). In particular, equal levels
of DAF-18::GFP expression were detected in the six VPCs of L2
larvae, and expression persisted in the descendants of the induced
VPCs until the Pn.pxxx stage (Figure 3). Interestingly, the sub-
cellular localization of DAF-18::GFP changed over the course of
vulval development. In the VPCs of L2 larvae prior to and during
induction (Pn.p stage), DAF-18::GFP was predominantly localized
in the cytoplasm and the nucleus (Figure 3A, 3B and 3B9).
However, at the subsequent stages (Pn.px to Pn.pxx stages), DAF-
18::GFP became increasingly localized to the plasma membrane of
the vulval cells (Figure 2C, 2D and 2D9). Plasma membrane
staining peaked at the ‘‘Christmas tree’’ (Pn.pxxx) stage, when
almost all the protein appeared to be localized to the membranes
and nuclear staining was reduced to very low levels (Figure 3E and
3F). Since the DAF-18::GFP reporter was also expressed in tissues
surrounding the vulval cells, we examined whether tissue-specific
expression of DAF-18 in the VPCs reduces vulval induction. For
this purpose, we expressed daf-18 cDNA fused to gfp under the
control of the Pn.p cell-specific lin-31 promoter, which is active in
the VPCs before and during vulval induction [29] (Plin-31::daf-18
cDNA::gfp::unc-54 39 UTR). Indeed, introduction of the lin-31::daf-
18::gfp transgene into daf-18(lf); let-23(rf) animals repressed vulval
induction with similar efficiency as the daf-18::gfp reporter or a
genomic daf-18 rescue construct (Figure 4).
Besides the vulval cells, the DAF-18::GFP reporter was also
expressed at the L3 to L4 larval stages in several cells of the uterus,
which is part of the somatic gonad (Figure 3). We thus tested if the
daf-18-mediated repression of vulval induction requires the gonad
by ablating the Z1 to Z4 somatic gonad and germline precursor
cells at the L1 stage. In gonad-ablated daf-18(lf) let-60(gf) double
mutants, vulval induction was higher than in gonad-ablated let-
60(gf) single mutants, indicating that DAF-18 represses vulval
induction independently of a signal from the gonad (Table 3, rows
15, 16). Thus, DAF-18 probably acts predominantly in the VPCs
to inhibit MAPK signaling during vulval induction.
Both lipid and protein phosphatase activities of DAF-18
inhibit vulval induction
Mammalian PTEN acts as a lipid phosphatase as well as a dual-
specificity protein phosphatase [5,6]. Moreover, a recent report
has shown that C. elegans DAF-18 can act as a protein phosphatase
inhibiting signaling by the VAB-1 ephrin receptor during oocyte
maturation [18]. The G129E mutation in the catalytic center of
human PTEN eliminates the lipid phosphatase activity, while
retaining the protein phosphatase activity [7]. The corresponding
glycine 174 residue in C. elegans DAF-18 was therefore mutated to
glutamic acid in the daf-18 genomic rescue construct. To quantify
the rescuing activity of the daf-18 wild-type (daf-18 wt) and the
G174E mutated lipid phosphatase mutant (daf-18 G174E), these
constructs were expressed in the daf-18(lf) let-60(gf) and let-23(rf);
daf-18(lf) backgrounds, and vulval induction was quantified. As
expected, expression of daf-18 wt rescued both the DAF-d (data not
shown) and vulval phenotypes of daf-18(lf) (Figure 5). In contrast,
daf-18 G174E did not rescue the DAF-d phenotype ([15] and own
observation), yet exhibited a weaker, though significant rescuing
activity of the vulval induction phenotype (Figure 5). These results
indicate that the DAF-18 protein and lipid phosphatase activities
each play independent roles in negatively regulating the RAS/
MAPK pathway and that both activities are required for the full
inhibition of vulval induction by DAF-18.
Table 3. Epistasis analysis of daf-18 with components of the
RAS/MAPK pathway.
genotype Induction±SE % Vul % Muv n
1 wild-type 3.0060.00 0.0 0.0 many
2 daf-18(lf) 2.9960.01 0.9 0.0 107
3 lin-3(lf) 0.8160.19 95.2 0.0 21
4 daf-18(lf) lin-3(lf) 0.4660.13 94.1 0.0 34
5 let-23(rf) 0.5560.08 93.8 0.0 129
6 let-23(rf); daf-18(lf) 1.9060.10***(5) 63.9 6.8 133
7 lin-2(lf) 1.3460.19 73.7 0.0 42
8 daf-18(lf); lin-2(lf) 2.5060.12***(7) 35.5 1.7 59
9 let-60(gf); sos-1(lf)# 2.6060.17 16.7 0.0 30
10 daf-18(lf) let-60(gf); sos-
1(lf)#
4.1960.12***(9) 0.0 90.3 31
11 lin-45(rf) 1.8160.15 57.3 0.0 68
12 daf-18(lf) lin-45(rf) 2.2960.17*(11) 39.5 2.3 42
13 mpk-1(lf) 0.0060.00 100 0.0 14
14 mpk-1(lf); daf-18(lf) 0.0060.00 100 0.0 17
15 let-60(gf) - gonad 2.4460.27 46 23 13
16 daf-18(lf) let-60(gf) -
gonad
3.3860.38 8 42 12
SE indicates the standard error of the mean. % Vul indicates the fraction of
animals with three or less induced VPCs. % Muv indicates the fraction of animals
with more than three induced VPCs. Induction indicates the average number of
induced VPCs per animal.
*indicates a p-value,0.05.
***indicates a p-value,0.0005, numbers in brackets indicates the row number
against which a t-test was performed. Alleles used: LG II: let-23(sy1), LG III: mpk-
1(ga117), LG IV: daf-18(ok480), let-60(n1046), lin-3(e1417), lin-45(sy96), LG V: sos-
1(s1031), LG X: lin-2(n397).
#sos-1(s1031) is cis-linked to unc-46(e177).
doi:10.1371/journal.pgen.1002881.t003
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Discussion
The Insulin pathway is a key regulator of development,
reproduction, and life span in metazoans. In this study, we have
discovered a new form of cross-talk between the Insulin and RAS/
MAPK pathways during vulval development. Signaling by the
Insulin receptor DAF-2 positively regulates MAPK activation.
Surprisingly, the effect of DAF-2 on vulval development does not
involve activation of the canonical Insulin pathway. DAF-2
signaling regulates vulval induction in at least two distinct
manners, through AGE-1 dependent and independent pathways
(Figure 6). One possible explanation for the AGE-1-independent
branch of DAF-2 signaling is supported by mammalian data,
which suggest that the Insulin receptor can directly stimulate RAS
activation by recruiting GRB2 and the RAS-GEF SOS [30,31].
Also in C. elegans, LET-60 RAS was found to act downstream of
the DAF-2 Insulin receptor to modulate the effects of Insulin
signaling during entry into the Dauer stage [32].
Figure 3. Expression pattern and sub-cellular localization of DAF-18::GFP. (A and B) Nomarski and fluorescence images of animals
expressing the DAF-18::GFP translational reporter at the Pn.p cell stage, (C and D) the Pn.px(x) stage and (E and F) the Pn.pxxx ‘‘Christmas tree’’ stage.
The insets in (B9) and (D9) show higher magnifications of the areas in (B) and (D) marked with dashed boxes.
doi:10.1371/journal.pgen.1002881.g003
Figure 2. DAF-18 inhibits MPK-1 phosphorylation. Total extracts of wild-type, daf-18(lf), let-60(gf) and daf-18(lf) let-60(gf) larvae at the L4 stage
were analyzed on Western blots using antibodies against (A) phosphorylated and total MEK-2 and (C) against di-phosphorylated (dp) and total MPK-1.
Signal intensities were quantified in four (for MEK-2) and three (for MPK-1) independent experiments, and the average ratios of (B) pMEK-2 to total
MEK-2 and (D) dpMPK-1 to total MPK-1 intensities were calculated.
doi:10.1371/journal.pgen.1002881.g002
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Furthermore, we found that the PTEN ortholog DAF-18
strongly inhibits RAS/MAPK signaling. Vulval induction in daf-
18(lf) let-60(gf) double mutants reaches levels similar to those seen
in the strongest Muv mutants such as lin-15AB(lf) [33]. The
increase in RAS/MAPK signaling in daf-18(lf) mutants could be
partially reverted by loss of the PI3K activity, suggesting that
elevated levels of PIP3 do stimulate RAS/MAPK signaling but
cannot explain all the functions DAF-18 exerts during vulval
induction. Accordingly, the inhibitory activity requires both the
lipid and protein phosphatase activities of DAF-18. PIP3 acts as a
second messenger that activates multiple downstream targets. One
major PIP3 target in the Insulin pathway is the AKT kinases,
which phosphorylate and thereby inhibits the FOXO transcription
factor DAF-16. However neither akt-1, akt-2 nor daf-16 mutations
had any detectable effect on vulval induction. Thus, PIP3 must act
via other targets to stimulate RAS/MAPK signaling. Increased
levels of PIP3 in the plasma membrane could, for example,
enhance the recruitment of an alternative GEF that activates RAS
Figure 4. DAF-18 expression in the Pn.p cells inhibits vulval induction. Vulval induction was scored at the L4 stage comparing let-23(rf); daf-
18(lf) animals carrying the different extra-chromosomal arrays (Ex[+]) to their siblings lacking the array (Ex[2]). Three independent lines were scored
per construct and at least 20 Ex[+] and Ex[2] animals were counted per line. For each line, a t-test was performed comparing induction in Ex[+] and
Ex[2] animals on the same plates. * indicates a p-value#0.05, ** a p-value#0.005, and *** a p-value#0.0005.
doi:10.1371/journal.pgen.1002881.g004
Figure 5. A lipid phosphatase deficient mutant of DAF-18 remains partially active. Animals carrying the daf-18 wt and daf-18 G174E extra-
chromosomal arrays were scored at the L4 stage as described in the legend to Figure 4.
doi:10.1371/journal.pgen.1002881.g005
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signaling in parallel to the RAS-GEF SOS-1 [28] (Figure 6).
However, we observed that prior to and at early stages of vulval
induction, DAF-18::GFP was localized predominantly in the
cytoplasm and nucleus of the VPCs, while membrane localization
of DAF-18 only became apparent at later stages. Previous
observations of mammalian PTEN localization suggested that
PTEN performs different functions depending on its sub-cellular
localization [34]. It has been proposed that the lipid phosphatase
activity is important for the cytoplasmic and membrane functions
of mammalian PTEN, while the protein phosphatase activity is
rather required for its nuclear functions [34,35]. The nuclear
localization of PTEN in mammalian cells is often associated with
cell-cycle arrest in G1 and accompanied by decreased levels of
ERK phosphorylation. Prior to vulval induction, the VPCs are
maintained in a long G1 arrest lasting the entire L2 stage [36]. It is
therefore possible that initially DAF-18 acts predominantly in the
nucleus as a protein phosphatase that negatively regulates vulval
induction. Indeed, Western blot analysis revealed elevated levels of
dpMPK-1 in daf-18(lf) mutants, supporting our model that DAF-
18 –directly or indirectly- blocks MAPK activation (Figure 6).
In humans, PTEN is one of the most frequently mutated tumor
suppressor genes. However, not all disease phenotypes associated
with loss of PTEN can be explained by hyper-activation of the
Insulin pathway alone. Thus, PTEN must have other functions
that are independent of its inhibitory activity in the Insulin
pathway. Accordingly, Suzuki and Han [19] observed many
synthetic phenotypes in C. elegans daf-18(lf) mutants, including
embryonic lethality and sterility, which are independent of DAF-
16 FOXO and do not involve DAF-2 InsR signaling. Our work
highlights the importance of C. elegans DAF-18 PTEN in regulating
a range of biological processes and may serve as a basis to better
understand the multiple roles human PTEN plays during cancer
initiation and progression. Thus, single mutations in the PTEN
tumor suppressor may result in the simultaneous hyper-activation
of several oncogenic signaling pathways.
Materials and Methods
General worm methods
Standard methods were used for maintaining and manipulating
Caenorhabditis elegans [37]. Animals were cultured at 20uC and the
wild-type strain is the Bristol N2 strain. Information regarding the
mutants used in this study can be found on WormBase (http://
www.wormbase.org). Mutations used according to their linkage
group:
LG I: daf-16(mu86), LG II: age-1(mg44), let-23(sy1), LG III: daf-
2(e1370), mpk-1(ga117), LG IV: let-60(n1046), daf-18(ok480), lin-
3(e1417), lin-45(sy96), LG V: akt-1(mg144gf), akt-1(ok525lf), LG X:
lin-2(n397), sos-1(s1031), unc-46(e177) to cis link sos-1(s1031), LG
X: lin-2(n397), gap-1(ga133). Transgenes used: syIs59[Pegl-17::cfp],
zhIs4[Plip-1::gfp], zhEx382[daf-18 genomic] zhEx343[daf-18::gfp],
zhEx358[Plin-31::daf-18::gfp], zhEx344[daf-18 G174E].
Plasmids and PCR fusion constructs
pIN05 (daf-18 genomic wt) was made by cloning the whole
genomic fragment of daf-18 starting 1.3 kb upstream of the ATG
and ending 0.5 kb downstream of the STOP and cloning to
pGEM-T. pIN03 (daf-18 genomic G174E) was made by fusion PCR
[38] of two overlapping fragments of the whole genomic daf-18
starting 1.3 kb upstream of the ATG and ending 0.5 kb
Figure 6. Multiple modes of crosstalk between the RAS/MAPK and insulin pathways during vulval development. Activation of LET-60
RAS in the VPCs causes phosphorylated MPK-1 to enter the nucleus where it phosphorylates transcription factors such as LIN-1 ETS, which represses
1u fate-specific gene expression. The insulin signaling pathway interacts with the RAS/MAPK pathway at several levels. Firstly, DAF-2 InsR activation
enhances RAS/MAPK signaling by stimulating the PI3K AGE-1, which positively regulates RAS/MAPK signaling via increased PIP3 production. In
addition, DAF-2 signaling activates the RAS/MAPK signaling independently of AGE-1, possibly by recruiting SEM-5 to the plasma membrane. DAF-18
PTEN inhibits RAS/MAPK signaling in two distinct manners; by dephosphorylating PIP3 and by negatively regulating MAPK activation.
doi:10.1371/journal.pgen.1002881.g006
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downstream of the STOP using primers which contain the
mutation G174E (GGC to GAA) in the overlapping region and
cloning to pGEM-T. pIN17 (Plin-31::daf-18 cDNA::gfp::unc-54
39UTR) was made by amplifying daf-18 cDNA::gfp from a
previously cloned plasmid with primers containing NotI sites on
both ends, digestion with NotI and cloning into the NotI site of the
pB253 plasmid containing the lin-31 enhancer and promoter. The
daf-18 genomic translational GFP reporter was made using fusion
PCR of three parts by inserting a gfp cassette in frame between the
last exon and the 39 UTR into a genomic fragment encompassing
1.3 kb of 59 regulatory sequences and the complete daf-18 coding
sequences. Sequences of the primers used for the different
constructs can be found in Table S1.
Transgenic lines
Worms expressing extra-chromosomal transgenic arrays were
generated by microinjection of DNA into young adult worms [39].
pIN03 (zhEx344), pIN05 (zhEx382) and pIN17(zhEx358) were
injected at a concentration of 50 ng/ml. The fusion PCR daf-18
genomic::gfp (zhEx343) translational reporter was injected at a
concentration of 30 ng/ul. Co-markers used were either pCFJ90
(Pmyo-2::mCherry) at a concentration of 2 ng/ul or pTJ1157
(Plin-48::gfp) at a concentration of 50 ng/ul. Final concentration
of injected DNA was filled up to 150 ng/ul using the empty
plasmid pBluescript-KS.
Fluorescence microscopy
DAF-18::GFP, Plip-1::GFP and Pegl-17::CFP expression were
observed under fluorescent light illumination with either a Leica
DMRA microscope equipped with a cooled CCD camera
(Hamamatsu ORCA-ER) or Olympus BX61 with Q Imaging
Fast 1394 Retiga 2000R camera (Q Imaging Inc., Canada)
controlled by the Openlab 5.x software (Improvision/PerkinEl-
mer). Animals were mounted on 4% agarose pads in M9 solution
with 20 mM tetramisole hydrochloride. Quantification of fluores-
cence levels was performed under the same picture acquisition
settings for all conditions examined.
Vulval induction
Vulval induction was scored by examining worms at the L4
stage under Nomarski optics as described [40]. The number of
VPCs that had adopted a 1u or 2u Vulval fate was counted for
each animal and the induction index was calculated by dividing
the number of 1u or 2u induced cells by the number of animals
scored. Statistical analysis was performed using a t-test for
independent samples.
RNA interference analysis
RNA interference analysis (RNAi) was performed by feeding
animals dsRNA-producing bacteria as described previously [41].
Around 10 to 20 P0 animals at the L1 larval stage were transferred
to plates containing RNAi bacteria grown on 3 mM IPTG. Vulval
induction was scored in the F1 generation (or the P0 for akt-2
RNAi) at the L4 larval stage to count the number of induced
VPCs. gfp, akt-2, piki-1 and vps-34 RNAi clones were all taken from
the Ahringer RNAi library.
Western blot analysis
Forty-five animals at the L4 stage were placed into 15 ml of 16
SDS sample buffer, lysed at 95uC for 5 min, centrifuged at
14,000 rpm for 2 min and the supernatant was loaded on 10%
acrylamide gels, which were analyzed by Western blotting. Anti-
phospho-MEK1/2 (S217/S221) and Anti-MEK1/2 (D1A5) anti-
bodies were purchased from Cell Signaling Technology (Beverly,
MA). Anti-di-phosphorylated ERK-1&2 (M8159) antibody was
purchased from Sigma-Aldrich (St. Louis, MO), and anti-ERK 2
(K-23) antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Quantification of the bands was performed
using the gel quantification plugin in ImageJ software [42]. The
ratios between phosphorylated and total MEK-2 and MPK-1
levels, respectively, were calculated and normalized for each
independent experiment to the ratios measured in the let-60(gf)
single mutants.
Supporting Information
Table S1 Primers used to generate the plasmids described in the
manuscript.
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